Sanofi faces dual setbacks as clinical trial and regulatory delays emerge

2 days ago

Louise Moon

"Indeed, two big setbacks for Sonophis. This is uh related to its experimental multiple cerosis drug. The first one is that they uh there's been a regulatory delay in the US. No reason was given for this and it had already been pushed back by 3 months in September. So that's a delay for regulatory approval. And then the second failure is uh a failure in a late stage clinical trial. So shares have declined in Safi the most in more than 3 months on the back of this kind of double whammy of of bad news. Analysts are saying, you know, this could threaten their their ability to hit peak sales for the year, peak annual sales. Um, and it's not the first hurdle they've faced with with this medicine. You know, there's been some some uh that trials have pointed to some risks already in in liver injuries."

The excerpt discusses significant setbacks for Sanofi due to a regulatory delay in the US and a late stage clinical trial failure. These issues have resulted in a decline in shares, and there are growing concerns over the drug's risks and its impact on peak annual sales.

Related Stocks